Comparison of Outcomes of In-Centre Haemodialysis Patients between the 1st and 2nd COVID-19 Outbreak in England, Wales, and Northern Ireland: A UK Renal Registry Analysis.

Autor:	Savino M; UK Renal Registry, Bristol, United Kingdom., Santhakumaran S; UK Renal Registry, Bristol, United Kingdom., Currie CSM; Department of Mathematical Sciences, University of Southampton, Southampton, United Kingdom., Onggo BSS; Department of Mathematical Sciences, University of Southampton, Southampton, United Kingdom., Evans KM; UK Renal Registry, Bristol, United Kingdom., Medcalf JF; UK Renal Registry, Bristol, United Kingdom.; University of Leicester, Leicester, United Kingdom.; Leicester General Hospital, Leicester, United Kingdom., Nitsch D; UK Renal Registry, Bristol, United Kingdom.; London School of Hygiene and Tropical Medicine, London, United Kingdom.; Royal Free London NHS Foundation Trust, London, United Kingdom., Steenkamp R; UK Renal Registry, Bristol, United Kingdom.
Jazyk:	angličtina
Zdroj:	Nephron [Nephron] 2022; Vol. 146 (5), pp. 469-480. Date of Electronic Publication: 2022 Mar 30.
DOI:	10.1159/000523731
Abstrakt:	Introduction: This retrospective cohort study compares in-centre haemodialysis (ICHD) patients' outcomes between the 1st and 2nd waves of the COVID-19 pandemic in England, Wales, and Northern Ireland. Methods: All people aged ≥18 years receiving ICHD at 31 December 2019, who were still alive and not in receipt of a kidney transplant at 1 March and who had a positive polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 31 January 2021, were included. The COVID-19 infections were split into two "waves": wave 1 from March to August 2020 and wave 2 from September 2020 to January 2021. Cumulative incidence of COVID-19, multivariable Cox models for risk of positivity, median, and 95% credible interval of reproduction number in dialysis units were calculated separately for wave 1 and wave 2. Survival and hazard ratios for mortality were described with age- and sex-adjusted Kaplan-Meier plots and multivariable Cox proportional models. Results: 4,408 ICHD patients had COVID-19 during the study period. Unadjusted survival at 28 days was similar in both waves (wave 1 75.6% [95% confidence interval [CI]: 73.7-77.5], wave 2 76.3% [95% CI 74.3-78.2]), but death occurred more rapidly after detected infection in wave 1. Long vintage treatment and not being on the transplant waiting list were associated with higher mortality in both waves. Conclusions: Risk of death of patients on ICHD treatment with COVID-19 remained unchanged between the first and second outbreaks. This highlights that this vulnerable patient group needs to be prioritized for interventions to prevent severe COVID-19, including vaccination, and the implementation of measures to reduce the risk of transmission alone is not sufficient. (© 2022 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu